spacer
home > pmps > spring 2020 > preparing for a world in flux
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Preparing for a World in Flux



According to a Lancet report, spending on climate change adaption is falling way short of the $100 billion a year commitment made under the Paris Agreement (1). Of this spending, less than 4% is channelled into health despite climate change threatening to undermine the last half-centuryís advances.

Itís true, there will be beneficial health impacts from milder winters that could help reduce the winter-time peak in deaths. Hotter than average summers could also help limit disease-transmitting mosquito populations, for example. However, scientists agree that most impacts will be adverse, with some declaring a public health emergency.

Current projections may look bleak, but if pharmaceutical and other large industries can collectively change their practices today, the climate crisis can be minimised and even potentially reversed.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author

Rich Quelch is an experienced global marketer within the healthcare and pharma sector. He has led the development of the Origin brand, positioning it as a world-leading supplier of innovative and groundbreaking pharma packaging devices, as well as offering a unique supply chain model that is disrupting the pharma industry.
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder


More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement